Gene info: ID 8542

Gene: APOL1

GENE ID: 8542

Synonyms: APO-L|APOL|APOL-I|FSGS4

Description: apolipoprotein L1

Gene type: protein-coding

Location: 22q12.3

dbXrefs: Ensembl:ENSG00000100342 MIM:603743 Vega:OTTHUMG00000030427 UniprotKB:O14791

RefSeq: NG_023228.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 5

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 3.249e-1 (AD) 1.190e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
APOL3	0.861
NLRC5	0.856
IL15RA	0.854
TAP1	0.845
SEMA3F	0.841
TRIM22	0.831
SLC15A3	0.831
PLA1A	0.829
SP100	0.828
CASP4	0.819

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
ZSCAN1	-0.412
MYADML2	-0.37
SMIM18	-0.36
SLC7A4	-0.349
KCNIP3	-0.348
CPLX3	-0.34
CRH	-0.336
CASC15	-0.336
NEUROD6	-0.331
ABCC12	-0.329

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01593	Zinc	Small Molecule	7440-66-6	Approved\|Investigational	Target

ID	Drug Name	Action	PubMed
D000082	Acetaminophen	Acetaminophen results in decreased expression of APOL1 mRNA	21420995\|2906747
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of APOL1 mRNA	21641981\|2715375
D000535	Aluminum	[APP protein modified form binds to Aluminum] which results in decreased expression of APOL1 mRNA	21298039
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of APOL1 mRNA	24449571
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of APOL1 mRNA	22316170
C006780	bisphenol A	bisphenol A results in increased expression of APOL1 mRNA	29275510
D000069286	Bortezomib	Bortezomib results in increased expression of APOL1 mRNA	20977926
C018475	butyraldehyde	butyraldehyde results in decreased expression of APOL1 mRNA	26079696
C039671	ciglitazone	[ciglitazone binds to PPARG protein alternative form] which results in increased expression of APOL1 mRNA	16197558
D016572	Cyclosporine	Cyclosporine results in decreased expression of APOL1 mRNA	25562108
D016572	Cyclosporine	Cyclosporine results in increased expression of APOL1 mRNA	20106945\|2214713
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of APOL1 mRNA]	27941970
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in increased expression of APOL1 mRNA	27392435
D002945	Cisplatin	Cisplatin promotes the reaction [jinfukang results in increased expression of APOL1 mRNA]	27392435
D002945	Cisplatin	Cisplatin results in increased expression of APOL1 mRNA	27392435
D002945	Cisplatin	jinfukang promotes the reaction [Cisplatin results in increased expression of APOL1 mRNA]	27392435
D002117	Calcitriol	Calcitriol results in increased expression of APOL1 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of APOL1 mRNA	21592394
D005020	Ethyl Methanesulfonate	Ethyl Methanesulfonate results in decreased expression of APOL1 mRNA	23649840
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in increased expression of APOL1 mRNA	27392435
C544151	jinfukang	Cisplatin promotes the reaction [jinfukang results in increased expression of APOL1 mRNA]	27392435
C544151	jinfukang	jinfukang promotes the reaction [Cisplatin results in increased expression of APOL1 mRNA]	27392435
C544151	jinfukang	jinfukang results in increased expression of APOL1 mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of APOL1 mRNA	23086925
D008345	Manganese	Manganese results in increased expression of APOL1 mRNA	17175027
C025340	manganese chloride	manganese chloride results in increased expression of APOL1 mRNA	17175027
D008741	Methyl Methanesulfonate	Methyl Methanesulfonate results in decreased expression of APOL1 mRNA	23649840
D009532	Nickel	APOL1 protein binds to Nickel	23896426
D009532	Nickel	Nickel results in increased expression of APOL1 mRNA	25583101
C025589	ochratoxin A	ochratoxin A results in decreased expression of APOL1 mRNA	19287073
D010100	Oxygen	Oxygen deficiency results in increased expression of APOL1 mRNA	20042640
D010936	Plant Extracts	Plant Extracts results in increased expression of APOL1 mRNA	23557933
D012643	Selenium	Selenium results in increased expression of APOL1 mRNA	19244175
C025462	sulindac sulfide	sulindac sulfide results in decreased expression of APOL1 mRNA	16184548
D014284	Triiodothyronine	Triiodothyronine results in decreased expression of APOL1 mRNA	23397585
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of APOL1 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of APOL1 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of APOL1 mRNA	20106945\|2163298
C016805	tris(1,3-dichloro-2-propyl)phosphate	"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of APOL1 mRNA"	26179874
D014520	Urethane	Urethane results in decreased expression of APOL1 mRNA	28818685
D014635	Valproic Acid	Valproic Acid results in decreased expression of APOL1 mRNA	29154799
D014638	Vanadates	Vanadates results in decreased expression of APOL1 mRNA	22714537
D014810	Vitamin E	Vitamin E results in increased expression of APOL1 mRNA	19244175
D015032	Zinc	APOL1 protein binds to Zinc	23896426

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005254	chloride channel activity	-	IDA	16020735
GO:0005515	protein binding	-	IPI	12621437 22582013 25416956
GO:0008289	lipid binding	-	IBA	21873635
GO:0008289	lipid binding	-	IDA	16020735

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006869	lipid transport	-	IEA	-
GO:0006898	receptor-mediated endocytosis	-	TAS	-
GO:0008203	cholesterol metabolic process	-	IEA	-
GO:0019835	cytolysis	-	IDA	12621437 17192540
GO:0031640	killing of cells of other organism	-	IDA	12621437 17192540
GO:0042157	lipoprotein metabolic process	-	IEA	-
GO:0043687	post-translational protein modification	-	TAS	-
GO:0044267	cellular protein metabolic process	-	TAS	-
GO:0045087	innate immune response	-	IDA	17192540
GO:1902476	chloride transmembrane transport	-	IDA	16020735

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005576	extracellular region	-	TAS	-
GO:0005615	extracellular space	-	IDA	17192540
GO:0005788	endoplasmic reticulum lumen	-	TAS	-
GO:0031224	intrinsic component of membrane	-	IC	16020735
GO:0034361	very-low-density lipoprotein particle	-	IDA	17154273
GO:0034364	high-density lipoprotein particle	-	IDA	9325276
GO:0072562	blood microparticle	-	HDA	22516433

KEGG ID	KEGG Term
hsa05143	African trypanosomiasis

Reactome ID	Reactome Term	Evidence
R-HSA-2168880	Scavenging of heme from plasma	TAS
R-HSA-2173782	Binding and Uptake of Ligands by Scavenger Receptors	TAS
R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	TAS
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-5653656	Vesicle-mediated transport	TAS
R-HSA-597592	Post-translational protein modification	TAS
R-HSA-8957275	Post-translational protein phosphorylation	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
27342958	APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume. (2016 Aug)	Freedman BI	Kidney Int
28572159	APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension). (2017 Sep)	Chen TK	Arterioscler Thromb Vasc Biol
23470819	Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. (2013 May)	Kopp JB	Curr Opin Nephrol Hypertens
26430087	Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression. (2015 Dec 7)	Chen TK	Clin J Am Soc Nephrol
25054777	APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. (2015 Jan)	Freedman BI	Kidney Int